These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1084 related articles for article (PubMed ID: 754992)
1. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol. Carlström K; Lunell NO; Zador G Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992 [TBL] [Abstract][Full Text] [Related]
2. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel. Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174 [TBL] [Abstract][Full Text] [Related]
3. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity. Rossmanith WG; Steffens D; Schramm G Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028 [TBL] [Abstract][Full Text] [Related]
4. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation. Letterie GS Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249 [TBL] [Abstract][Full Text] [Related]
5. Pituitary and ovarian function in women receiving hormonal contraception. Cohen BL; Katz M Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456 [TBL] [Abstract][Full Text] [Related]
6. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids. Scott JA; Brenner PF; Kletzky OA; Mishell DR Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817 [TBL] [Abstract][Full Text] [Related]
7. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis. Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162 [TBL] [Abstract][Full Text] [Related]
8. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles. Landgren BM; Diczfalusy E Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642 [TBL] [Abstract][Full Text] [Related]
9. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. London RS; Chapdelaine A; Upmalis D; Olson W; Smith J Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557 [TBL] [Abstract][Full Text] [Related]
10. The mechanism of action of a new low-dosed combined oral contraceptive. Dericks-Tan JS; Schneider K; Taubert HD Arch Gynecol; 1980; 229(2):107-14. PubMed ID: 6768343 [TBL] [Abstract][Full Text] [Related]
11. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest. Spona J; Feichtinger W; Kindermann C; Moore C; Mellinger U; Walter F; Gräser T Contraception; 1997 Sep; 56(3):185-91. PubMed ID: 9347211 [TBL] [Abstract][Full Text] [Related]
12. The effect of norethisterone (500 mcg) and ethinyl estradiol (35 mcg) capsules on the pituitary-ovarian axis. Nuttall ID; Elstein M; Fahmy DR Contraception; 1982 May; 25(5):463-9. PubMed ID: 6809424 [TBL] [Abstract][Full Text] [Related]
13. Effects of low dose oral contraceptives containing norethindrome and ethinyl estradiol on serum levels of progesterone and pituitary gonadotropins. McGuire JL; Bariso CD; Yuliano E; Hume RJ; Pasquale SA Contraception; 1975 Mar; 11(3):329-38. PubMed ID: 1116369 [TBL] [Abstract][Full Text] [Related]
14. Pulsatile luteinizing hormone patterns in long term oral contraceptive users. Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046 [TBL] [Abstract][Full Text] [Related]
15. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins. Goldzieher JW; de la Peña A; Chenault CB; Cervantes A Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928 [TBL] [Abstract][Full Text] [Related]
16. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants. Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017 [TBL] [Abstract][Full Text] [Related]
17. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622 [TBL] [Abstract][Full Text] [Related]
18. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. van Heusden AM; Fauser BC Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868 [TBL] [Abstract][Full Text] [Related]
19. Ovulation inhibition with a combined oral contraceptive containing 20 micrograms ethinyl estradiol and 250 micrograms levonorgestrel. Serum levels of the active ingredients and FSH, LH, estradiol 17-beta and progesterone. Lunell NO; Carlström K; Zador G Acta Obstet Gynecol Scand Suppl; 1979; 88():17-21. PubMed ID: 294110 [TBL] [Abstract][Full Text] [Related]
20. Serum gonadotropin and ovarian steroid levels in women during administration of a norethindrone-ethinylestradiol triphasic oral contraceptive. Ling WY; Johnston DW; Lea RH; Bent AE; Scott JZ; Toews MR Contraception; 1985 Oct; 32(4):367-75. PubMed ID: 3935373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]